Efficacy and tolerability at 3 and 6 months following use of azathioprine for recalcitrant atopic dermatitis in children and young adults

Journal of Dermatological Treatment

Volumn 20, Issue 3, 2009, Pages 141-145

  Hon, Kam Lun E ^a   Ching, Gary K W ^a   Leung, Ting Fan ^a   Chow, Chung Mo ^a   Lee, Kenneth K C ^a   Ng, Pak Cheung ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Azathioprine; Childhood atopic dermatitis

Indexed keywords

ANTIHISTAMINIC AGENT; AZATHIOPRINE; IMMUNOGLOBULIN E; STEROID;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ATOPIC DERMATITIS; BILIRUBIN BLOOD LEVEL; CHILD; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL FEATURE; COMPARATIVE STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; FEMALE; HUMAN; KIDNEY FUNCTION; LIVER FUNCTION; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PRURITUS; SCORING SYSTEM; SEX DIFFERENCE; SIDE EFFECT; STAPHYLOCOCCUS AUREUS; TREATMENT DURATION; VISUAL ANALOG SCALE;

ADOLESCENT; AGE FACTORS; AZATHIOPRINE; CHILD; DERMATITIS, ATOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MAXIMUM TOLERATED DOSE; PROBABILITY; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX FACTORS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 67651098812     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.1080/09546630802512646     Document Type: Article

References (13)

1. Hon KL, Kam WY, Lam MC, Leung TF, Ng PC. CDLQI, SCORAD and NESS: Are they correlated? Qual Life Res. 2006;15:1551-8.
2. Leung AK, Hon KL, Robson WL. Atopic dermatitis. Adv Pediatr. 2007;54:241-73.
3. Ellison JA, Patel LM, Ray DW, David TJ, Clayton PF. Hypothalamic- pituitary-adrenal function and glucocorticoid sensitivity in atopic dermatitis. Pediatrics. 2000;105:794-9.
4. Murphy LA, Atherton D. A retrospective evaluation of azathioprine in severe childhood atopic eczema, using thiopurine methyltransferase levels to exclude patients at high risk of myelosuppression. Br J Dermatol. 2002;147:308-15.
5. Young AR. Carcinogenicity of UVB phototherapy assessed. Lancet. 1995;345:1431-2.
6. Buckley DA, Baldwin P, Rogers S. The use of azathioprine in severe adult atopic eczema. J Eur Acad Dermatol Venereol. 1998;11:137-40.
7. Meggitt SJ, Reynolds NJ. Azathioprine for atopic dermatitis. Clin Exp Dermatol. 2001;26:369-75.
8. Berth-Jones J, Takwale A, Ta n E, Barclay G, Agarwal S, Ahmed I, et al. Azathioprine in severe adult atopic dermatitis: A double-blind, placebo-controlled, crossover trial. Br J Dermatol. 2002;147:324-30.
9. Hernandez JS, Van Loon JA, Otterness DM, Guerciolini R, Weinshilboum RM. Thiopurine methyltransferase regulation in rat kidney: Immunoprecipitation studies. Xenobiotica. 1991;21:451-9.
10. Tinel M, Berson A, Pessayre D, Letteron P, Cattoni MP, Horsmans Y, et al. Pharmacogenetics of human erythrocyte thiopurine methyltransferase activity in a French population. Br J Clin Pharmacol. 1991;32:729-34.
11. Jacqz-Aigrain E, Bessa E, Medard Y, Mircheva Y, Vilmer E. Thiopurine methyltransferase activity in a French population: h.p.l.c. assay conditions and effects of drugs and inhibitors. Br J Clin Pharmacol. 1994;38:1-8.
12. Hon KL, Lam MC, Leung TF, Wong KY, Chow CM, Fok TF, et al. Are age-specifc high serum IgE levels associated with worse symptomatology in children with atopic dermatitis? Int J Dermatol. 2007;46:1258-62.
13. Murphy LA, Atherton DJ. Azathioprine as a treatment for severe atopic eczema in children with a partial thiopurine methyl transferase (TPMT) defciency. Pediatr Dermatol. 2003;20:531-4.